Personalis Inc
NASDAQ:PSNL
Personalis Inc
Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company is headquartered in Menlo Park, California and currently employs 325 full-time employees. The company went IPO on 2019-06-20. The firm is focused on the development of therapies by providing molecular data about each patient's cancer and immune response. The company provides sequencing and data analysis services to support the development of cancer therapies. Its NeXT Platform, which provides its biopharmaceutical customers with information on over 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover over 50 to 500 genes. Its NeXT Platform is designed to provide analysis of both a tumor and its immune microenvironment from a single limited tissue sample. Its platform covers the deoxyribonucleic acid sequence of all of the approximately 20,000 human genes. The company also reports on transcriptome of a tumor, which encompasses ribonucleic acid expression across human genes, allowing it to determine which of the genomic mutations might actually be driving tumor progression.
Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company is headquartered in Menlo Park, California and currently employs 325 full-time employees. The company went IPO on 2019-06-20. The firm is focused on the development of therapies by providing molecular data about each patient's cancer and immune response. The company provides sequencing and data analysis services to support the development of cancer therapies. Its NeXT Platform, which provides its biopharmaceutical customers with information on over 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover over 50 to 500 genes. Its NeXT Platform is designed to provide analysis of both a tumor and its immune microenvironment from a single limited tissue sample. Its platform covers the deoxyribonucleic acid sequence of all of the approximately 20,000 human genes. The company also reports on transcriptome of a tumor, which encompasses ribonucleic acid expression across human genes, allowing it to determine which of the genomic mutations might actually be driving tumor progression.
Revenue Guidance Lowered: Personalis lowered its full-year 2025 revenue guidance to $68–73 million from the previous range of $70–80 million, due to ongoing biopharma project variability and logistical delays.
Strong Clinical Test Growth: The company delivered 4,388 clinical tests in Q3, up 26% sequentially and 364% year-over-year, reaching its year-end volume target one quarter early.
Biopharma Revenue Volatility: Biopharma revenue was impacted by the completion of key projects and logistical issues with sample shipments, leading to lumpy quarterly results.
MRD Adoption Momentum: Over 700 physicians are now ordering NeXT Personal, and clinical adoption is seen as a major driver for future high-margin growth once reimbursement is secured.
Reimbursement Progress: Three MolDX dossiers are under review, with the company remaining confident in achieving two coverage decisions by year-end, though final timing depends on MolDX.
Financial Discipline Maintained: Despite lower revenue guidance, cash usage guidance remains unchanged at $75 million for 2025, highlighting proactive cost management.
Gross Margin Impacted: Gross margin declined to 13.2% due to lower revenue and investments in unreimbursed clinical test costs, but is expected to exceed 50% in the long term after reimbursements are secured.
